[PHP279] Potential Societal Value of Biosimilars Adoption: The Example of UK
2015 Value in Health
Mendoza, C. | Ionescu, D. | Radière, G. | Rémuzat, C. | Lee, D. | Toumi, M. |
Launch of innovative therapies such as biologics adds substantial burden on national healthcare insurance systems. Rising costs of such innovative therapies led to the implementation of cost-containments measures, including denied or restricted reimbursement compared to licensed indications. Biosimilars’ introduction might decrease costs and increase access to biologics. The objective of this study was to assess the opportunity of indication extension with current and future biosimilars taking the example of the United Kingdom (UK).